HBF-0259

• CAT Number: I007191
• CAS Number: 957011-15-3
• Molecular Formula: C16H12Cl2FN5
• Molecular Weight: 364.2
• Purity: ≥95%
• Synonyms: HBF-0259; HBF 0259; HBF0259.;7-(2-Chloro-6-fluorophenyl)-5-(4-chlorophenyl)-1,5,6,7-tetrahydrotetrazolo[1,5-a]pyrimidine
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: 7-(2-chloro-6-fluorophenyl)-5-(4-chlorophenyl)-4,5,6,7-tetrahydrotetrazolo[1,5-a]pyrimidine
• InChI: InChI=1S/C16H12Cl2FN5/c17-10-6-4-9(5-7-10)13-8-14(24-16(20-13)21-22-23-24)15-11(18)2-1-3-12(15)19/h1-7,13-14H,8H2,(H,20,21,23)
• InChIKey: BRBZPYDLUUWBCD-UHFFFAOYSA-N
• SMILES: C1C(NC2=NN=NN2C1C3=C(C=CC=C3Cl)F)C4=CC=C(C=C4)Cl

HBF-0259（Cat No.:I007191） is a newly discovered inhibitor that targets the secretion of the hepatitis B virus surface antigen (HBsAg). It was found to be effective against HBsAg, with an EC50 value of 11.3 μM and a CC50 value of >50 μM in HepG2.2.15 cells. The compound had a 50% effective concentration of approximately 1.5 microM in a secondary HBV-expressing cell line, with a concentration that exhibited 50% cytotoxicity of >50 microM.

Reference

1:Virusdisease. 2016 Sep;27(3):234-241. doi: 10.1007/s13337-016-0333-9. Epub 2016 Aug 11. Prediction of HBF-0259 interactions with hepatitis B Virus receptors and surface antigen secretory factors.Mohebbi A,Mohammadi S,Memarian A, PMID: 28466034 PMCID: PMC5394709 [Available on 2017-09-01] DOI: 10.1007/s13337-016-0333-9 Abstract: Hepatitis B virus (HBV) is an etiological agent of viral hepatitis, which may lead to cirrhosis, and hepatocellular carcinoma. Current treatment strategies have not shown promising effect to date but various complications such as, drug toxicity-resistance have been reported. Study on newly discovered compounds, with minimal side effects, as specific HBV inhibitors is a fundamental subject introducing new biologic drugs. Here, we aimed to, by prediction, estimate interactions of HBF-0259 as a non-toxic anti-HBV compound on inhibiting the HBV through either interaction with the viral entry or HBsAg secreting factors using In Silico procedure. Molecular docking was performed by Hex 8.0.0 software to predict the interaction energy (Etot) between HBF-0259 and known cellular factors involved in HBV entry and HBsAg secreting factors. Hex 8.0.0 also employed to create protein-protein complexes. These interactions were then used to analyze the binding site of HBF-0259 within the assumed receptors by MGLTools software. Finally, the amino acid sequences involved in this interaction were aligned for any conservancy. Here, we showed that HBF-0259 Etot with CypA (-545.41 kcal/mol) and SCCA1 (499.68 kcal/mol), involved in HBsAg secretion and HBV integration, respectively, was higher than other interactions. Furthermore, HBF-0259 predicted interaction energy was even higher than those of CypA inhibitors. In addition, we claim that preS1 and/or preS2 regions within HBsAg are not suitable targets for HBF-0259. HBF-0259 has higher interaction energy with CypA and SCCA1, even more than other known receptors, co-receptors, viral ligands, and secretory factors. HBF-0259 could be introduced as potent anti-viral compound in which CypA and or SCCA1, as previously shown, are involved.